SEC Filing Summary: Capricor Therapeutics, Inc. (CAPR)
Business Context and Reporting Period
This Form 8-K, dated November 10, 2025, reports the financial results for Capricor Therapeutics, Inc. for the quarter ended September 30, 2025. The filing serves as a current report to announce the release of third-quarter 2025 financial results and a corporate update, which are detailed in the attached press release (Exhibit 99.1).
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1) but are not disclosed in the body of this Form 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing indicates that a corporate update was provided alongside the financial results in the attached press release. However, the text of this Form 8-K does not include specific details on guidance, outlook, management commentary, risks, contingencies, or unusual items. The information furnished under Item 2.02 is explicitly stated as not being deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the corporate update.
- Confirm if there were any changes in the company's liquidity position or debt obligations since the last reporting period.